Home
Clinical Resources Search
PQI: Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

Download PQI pdf

Last Updated: September 2, 2023

By: Houston Holmes, MD

About this PQI

This PQI will discuss the initiation and management of tazemetostat in the treatment of relapsed or refractory (R/R) follicular lymphoma (FL).

More About This PQI

PQI in Action Articles:

Tazemetostat_tazverik_lymphoma pdf

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma

PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer

PQI: Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment

PQI in Action: Inavolisib (Itovebi) Patient Management

PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

S11 E7: Your Health Story in One Place

S11 E6: Finding the Heart of Oncology

S11 E5: Keep Marching On: Changing the Story of Pancreatic Cancer

S11 E4: From Data to Decisions: Decoding Prostate Cancer Updates

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bispecific (T-Cell Engager)

Treatment Support Kit: Zanidatamab-hrii

Treatment Support Kit: Avutometinib and Defactinib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Tafasitamab, Rituximab, and Lenalidomide

PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

Obinutuzumab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Obinutuzumab and Cyclophosphamide, Vincristine, and Prednisone

Dexamethasone, Etoposide, Ifosfamide, and Carboplatin

Nivolumab and Ifosfamide, Carboplatin, and Etoposide

Pemetrexed

Topotecan

PQI in Action: Tazemetostat (Tazverik®)Management in Relapsed/Refractory Follicular Lymphoma

PQI in Action: Tazemetostat (Tazverik®)Management in Relapsed/Refractory Follicular Lymphoma

Enzalutamide

Talazoparib and Enzalutamide

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Enzalutamide (Xtandi®) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

Trastuzumab, Carboplatin, and Paclitaxel

Pembrolizumab, Bevacizumab, Cisplatin, and Paclitaxel

Etoposide, Methotrexate, Dactinomycin, Cyclophosphamide, and Vincristine

Isatuximab-irfc (SARCLISA ESCENA) with the CirCLIQ On-Body Delivery System: Treatment Discussion Guide